Cue Biopharma Inc

Cue Biopharma Inc has a strong liquidity position, with $27.14 million in cash and equivalents, representing 64.3% of its total assets of $42.21 million. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. The current ratio of 2.74 suggests the company is well-positioned to meet its short-term obligations. The company is currently unprofitable, with a net loss of $26.60 million and an operating loss of $26.55 million. Its return on equity is -100.64%, and return on assets is -63.02%, both significantly below the industry median for biotechnology firms. The price-to-book ratio of 3.12 and price-to-tangible-book ratio of 3.12 suggest the market is valuing the company's intangible assets at a premium, despite its current unprofitability. Cue Biopharma Inc does not disclose segment or geographic revenue breakdowns in its latest financials, making it difficult to assess revenue concentration or geographic exposure. The company's operations are likely centered in the United States, as is typical for biotechnology firms, but no specific geographic data is available. The company's revenue of $27.47 million represents a modest base, but with no disclosed historical revenue growth rates, it is unclear whether this reflects a stable or growing business. The company is expected to remain in a development phase, with no indication of near-term revenue growth acceleration. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, with basic and diluted shares outstanding being equal at 3.26 million. No recent dilutive events or forward-looking dilution risks are disclosed in the latest filings. Recent investor relations data shows a mean price target of $120.00, significantly higher than the current market price of $25.33. However, the mean recommendation of 2.00 (Buy) is supported by only one Buy rating, with no Strong Buy or Hold ratings, suggesting limited analyst confidence in the stock's near-term performance.